Axogen, Inc. (LON: 0HKD)

Market Cap	674.99M
Revenue (ttm)	134.94M
Net Income (ttm)	-10.67M
Shares Out	n/a
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	216
Average Volume	2,010
Open	19.03
Previous Close	18.75
Day's Range	18.73 - 19.03
52-Week Range	3.50 - 19.03
Beta	0.76
RSI	65.63
Earnings Date	Mar 4, 2025

About Axogen

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submuc...

• Industry: Medical - Equipment & Services
• Sector: Healthcare
• Employees: 428
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HKD

Financial Performance

In 2023, Axogen's revenue was $159.01 million, an increase of 14.74% compared to the previous year's $138.58 million. Losses were -$21.72 million, -24.98% less than in 2022.

Financial numbers in USD